Download Image
    
Share
  
Post
TRV027 for COVID-19
2 studies with 318 patients
Hospital Icon Control
Hospital Icon TRV027 Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 TRV027 studies. Nov 2025. c19early.org
0 0.5 1 1.5+ All studies -54% Mortality -54% RCTs -54% RCT mortality -54% Late -54% FavorsTRV027 Favorscontrol
Apr 11
2023
 Self et al., JAMA, doi:10.1001/jama.2023.3546 Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor–Biased Ligand in Adults With COVID-19
52% higher mortality (p=0.25) and 35% worse recovery (p=0.17). Two RCTs of 510 hospitalized COVID-19 patients showing no significant difference in mortality or days alive without supplemental oxygen with either TRV027 (angiotensin II type 1 receptor-biased ligand) or TXA127 (synthetic angiotensin 1-7..
Dec 14
2022
 Robbins et al., British Journal of Clinical Pharmacology, doi:10.1111/bcp.15618 The effect of TRV027 on coagulation in COVID‐19: A pilot randomized, placebo‐controlled trial
73% higher mortality (p=1). Double-blind RCT 30 hospitalized COVID-19 patients in the United Kingdom showing a non-statistically significant trend towards decreased D-dimer levels with TRV027, an angiotensin-(1-7) analogue, compared to placebo. The trial was termina..